Volume 12, Issue 4 (12-2024)
J Surg Trauma 2024, 12(4): 129-136 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ebrahimi Shah-abadi M, Heydari M, Najmaddini M, Soltani E. Outcomes of Hemostatic Management in Hemophilia Patients without Inhibitors Undergoing Invasive or Surgical Procedures: A Systemic Review and Meta-analysis. J Surg Trauma 2024; 12 (4) :129-136
URL: http://jsurgery.bums.ac.ir/article-1-386-en.html
URL: http://jsurgery.bums.ac.ir/article-1-386-en.html
Assistant fellowship of Surgical Oncology, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract: (395 Views)
Introduction: There are numerous questions surrounding the use, duration of administration, and dosage of clotting factor concentrates (CFC). This issue has been so far very controversial and challenging. Given the critical oitre1importance of the subject, the present study aimed to assess the outcomes of perioperative hemostatic management in hemophilia patients without inhibitors undergoing invasive or surgical procedures.
Methods: All articles published in international databases, such as PubMed, Scopus, Science Direct, and Embase, until May 2022 were included. Data analysis was performed using STATA software (version 16).
Results: The search in databases yielded 1,218 articles and the full text of 192 articles was reviewed. Finally, nine articles that met the inclusion criteria entered the analysis. Mean differences of bleeding rate between high-dose prophylaxis and episodic groups was -53.40 (MD; 95 CI (-53.72, -53.08); P=0.01). The mean differences of joint bleeding rate between intermediate dose prophylaxis and episodic groups was -12.79 (MD; 95 CI (-12.85, -12.74); P=0.01).
Conclusion: Based on the present meta-analysis, it was revealed that in patients with hemophilia A, the use of prophylaxis has better results in terms of annualized bleeding rate and annualized joint bleeding rate than episodic treatment.
Methods: All articles published in international databases, such as PubMed, Scopus, Science Direct, and Embase, until May 2022 were included. Data analysis was performed using STATA software (version 16).
Results: The search in databases yielded 1,218 articles and the full text of 192 articles was reviewed. Finally, nine articles that met the inclusion criteria entered the analysis. Mean differences of bleeding rate between high-dose prophylaxis and episodic groups was -53.40 (MD; 95 CI (-53.72, -53.08); P=0.01). The mean differences of joint bleeding rate between intermediate dose prophylaxis and episodic groups was -12.79 (MD; 95 CI (-12.85, -12.74); P=0.01).
Conclusion: Based on the present meta-analysis, it was revealed that in patients with hemophilia A, the use of prophylaxis has better results in terms of annualized bleeding rate and annualized joint bleeding rate than episodic treatment.
Type of Study: Meta-analysis |
Subject:
General Surgery
Received: 2023/06/23 | Accepted: 2024/12/15 | ePublished ahead of print: 2024/12/21 | Published: 2024/12/30
Received: 2023/06/23 | Accepted: 2024/12/15 | ePublished ahead of print: 2024/12/21 | Published: 2024/12/30
References
1. Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019;104(9):1702. [DOI:10.3324/haematol.2019.221093]
2. Knöbl P. Prevention and management of bleeding episodes in patients with acquired hemophilia A. Drugs. 2018;78(18):1861-1872. [DOI:10.1007/s40265-018-1027-y]
3. Cooley B, Broze Jr GJ, Mann DM, Lin F-C, Pedersen LG, Stafford DW. Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model. Blood. 2019;133(22):2445-2451. [DOI:10.1182/blood.2018884015]
4. Matino D, Makris M, Dwan K, D'Amico R, Iorio A. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2015;2015(12):CD004449. [DOI:10.1002/14651858.CD004449.pub4]
5. Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia. 2003;9(4):405-417. [DOI:10.1046/j.1365-2516.2003.00779.x]
6. Tong K-M, Wang J-D, Chang S-T, Cheng Y-Y, Wang S-S. Outcome of perioperative hemostatic management in patients with hemophilia without inhibitors undergoing 161 invasive or surgical procedures. J Chin Med Assoc. 2018;81(10):926-929. [DOI:10.1016/j.jcma.2017.11.016]
7. Abou-Ismail MY, Connell NT. How to manage bleeding disorders in aging patients needing surgery. Hematology. 2021;2021(1):529-535. [DOI:10.1182/hematology.2021000288]
8. Chen X, Miao Q, Zhu T, Zhang C. Replacement Therapy for Hemophilia Patients Undergoing Cardiac Surgery: Report of Three Cases. Chin Med Sci J. 2022;37(1):79-81. [DOI:10.24920/003929]
9. Dhal B, Dutta A, Buragohain M, Rajan A. Fracture Shaft of Femur in PwH (person with hemophilia): Surgery or conservative? Assam J Internal Med. 2021;11(1):40-44 [DOI:10.4103/2278-8239.346809]
10. Rudowski W. Moynihan Lecture, 1980. Major surgery in haemophilia. Ann R Coll Surg Engl. 1981;63(2):111.
11. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr. 1996;129(3):424-431. [DOI:10.1016/S0022-3476(96)70076-8]
12. Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients. Eur J Haematol. 2019;102(2):111-122. [DOI:10.1111/ejh.13193]
13. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding‐related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011:(9):CD003429. [DOI:10.1002/14651858.CD003429.pub4]
14. Rodriguez‐Merchan E. Surgical wound healing in bleeding disorders. Haemophilia. 2012;18(4):487-490. [DOI:10.1111/j.1365-2516.2012.02760.x]
15. Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. HSS J. 2010;6(1):37-42. [DOI:10.1007/s11420-009-9140-9]
16. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020; 26 Suppl 6:1-158. [DOI:10.1111/hae.14046]
17. Delgado-Flores CJ, García-Gomero D, Salvador-Salvador S, Montes-Alvis J, et al . Effects of replacement therapies with clotting factors in patients with hemophilia: A systematic review and meta-analysis. PloS One. 2022;17(1): e0262273. [DOI:10.1371/journal.pone.0262273]
18. Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83(3):217-220. [DOI:10.1097/JCMA.0000000000000270]
19. Chozie NA, Primacakti F, Gatot D, Setiabudhy RD, Tulaar AB, Prasetyo M. Comparison of the efficacy and safety of 12‐month low‐dose factor VIII tertiary prophylaxis vs on‐demand treatment in severe haemophilia A children. Haemophilia. 2019;25(4):633-639. [DOI:10.1111/hae.13770]
20. Manco‐Johnson MJ, Lundin B, Funk S, Peterfy C, Raunig D, Werk M, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost. 2017;15(11):2115-2124. [DOI:10.1111/jth.13811]
21. Verma S, Dutta T, Mahadevan S, Nalini P, Basu D, Biswal N, et al. A randomized study of very low‐dose factor VIII prophylaxis in severe haemophilia-A success story from a resource limited country. Haemophilia. 2016;22(3):342-348. [DOI:10.1111/hae.12838]
22. Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou‐Stoeter D, Maas Enriquez M, et al. Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360-369. [DOI:10.1111/jth.12828]
23. Valentino L, Rusen L, Elezovic I, Smith L, Korth‐Bradley J, Rendo P. Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia. 2014;20(3):398-406. [DOI:10.1111/hae.12344]
24. Valentino L, Mamonov V, Hellmann A, Quon D, Chybicka A, Schroth P, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359-367. [DOI:10.1111/j.1538-7836.2011.04611.x]
25. Powell J, Martinowitz U, Windyga J, Di Minno G, Hellmann A, Pabinger I, et al. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. Thromb Haemost. 2012;108(11):913-922. [DOI:10.1160/TH12-03-0188]
26. Gringeri A, Lundin B, Von Mackensen S, Mantovani L, Mannucci P, Group ES. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9(4):700-710. [DOI:10.1111/j.1538-7836.2011.04214.x]
27. Manco-Johnson M, Abshire T, Shapiro A. Recombinant factor VIII for the prevention of joint disease in children with severe hemophilia: prophylaxis compared with episodic treatment. N Engl J Med. 2007;357(6):535-544. [DOI:10.1056/NEJMoa067659]
28. Zhao Y, Xiao J, Yang R, Wu R, Hu Y, Beckmann H, et al. Efficacy of standard prophylaxis versus on-demand treatment with Bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A. Pediatr Hematol Oncol. 2017;34(3):138-148. [DOI:10.1080/08880018.2017.1313921]
29. Wu R, Luke KH, Poon MC, Wu X, Zhang N, Zhao L, et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia. 2011;17(1):70-74. [DOI:10.1111/j.1365-2516.2010.02348.x]
30. Qiu S-Q, Zhuang J-M, Zhou X, Yin R-X, Liu Z-Q, Ma F, et al. Breakthrough bleeding in adult patients with severe hemophilia A receiving low-and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors. Nan Fang Yi Ke Da Xue Xue Bao. 2017;37(10):1391-1395.
31. Zhuang J-M, Sun X-Y, Zhou X, Liu Z-Q, Sun J. Prophylactic treatment with low-and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis. Nan Fang Yi Ke Da Xue Xue Bao. 2018;38(4):496-501.
32. Fischer K, Steen Carlsson K, Petrini P, Holmström M, Ljung R, van den Berg HM, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood. 2013;122(7):1129-1136. [DOI:10.1182/blood-2012-12-470898]
33. Wang Y, Yang Q, Zheng L, Wang X, Jiang W, Lu L, et al. Efficacy of Individualized Preventive Treatment of Patients with Severe Hemophilia A Guided by Multiple Clinical Parameters and Pharmacokinetics. Acta Haematol. 2022;145(4):354-361. [DOI:10.1159/000521360]
34. Hermans C, Makris M. 'Haemophilia Guidelines for All': A new ambition of the World Federation of Haemophilia (WFH). Haemophilia. 2020;26(5):748-749. [DOI:10.1111/hae.14093]
35. Srivastava A, Brewer A, Mauser‐Bunschoten E, Key N, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1): e1-e47. [DOI:10.1111/j.1365-2516.2012.02909.x]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Attribution-NoneCommercial CC BY-NC
